BSC has launched a new spin-off, ELEM Biotech, which will allow companies of medical technologies, pharmaceuticals, CROs and doctors to perform virtual simulations for the personalized treatment of some diseases.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.